RT Journal Article
SR Electronic
T1 Maternal immune response and placental antibody transfer after COVID-19 vaccination across trimester and platforms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.12.21266273
DO 10.1101/2021.11.12.21266273
A1 Atyeo, Caroline G.
A1 Shook, Lydia L.
A1 Brigida, Sara
A1 De Guzman, Rose M.
A1 Demidkin, Stepan
A1 Muir, Cordelia
A1 Akinwunmi, Babatunde
A1 Baez, Arantxa Medina
A1 McSweeney, Erin
A1 Burns, Madeleine
A1 Nayak, Ruhi
A1 Kumar, Maya K.
A1 Patel, Chinmay D.
A1 Fialkowski, Allison
A1 Cvrk, Dana
A1 Goldfarb, Ilona T.
A1 Yonker, Lael M.
A1 Fasano, Alessio
A1 Elovitz, Michal A.
A1 Gray, Kathryn J.
A1 Alter, Galit
A1 Edlow, Andrea G.
YR 2021
UL http://medrxiv.org/content/early/2021/11/14/2021.11.12.21266273.abstract
AB The availability of three COVID-19 vaccines in the United States provides an unprecedented opportunity to examine how vaccine platforms and timing of vaccination in pregnancy impact maternal and neonatal immunity. Here, we characterized the antibody profile after Ad26.COV2.S, mRNA-1273 or BNT162b2 vaccination in 158 pregnant individuals, and evaluated transplacental antibody transfer by profiling maternal and umbilical cord blood in 175 maternal-neonatal dyads. These analyses revealed lower vaccine-induced functions and Fc-receptor binding after Ad26.COV2.S compared to mRNA vaccination, and subtle advantages in titer and function with mRNA-1273 versus BN162b2. mRNA vaccinees had higher titers and functions against SARS-CoV-2 variants of concern. First and third trimester vaccination resulted in enhanced maternal immune responses relative to second trimester. Higher cord:maternal transfer ratios following first and second trimester vaccination reflect placental compensation for waning maternal titers. These results support vaccination early in pregnancy to maximize maternal protection throughout gestation, without compromising neonatal antibody protection.Competing Interest StatementK.J.G. has consulted for Illumina, BillionToOne, and Aetion outside the scope of the submitted work. G.A. is the founder of Seromyx Inc. M.A.E. reported serving as medical advisor for Mirvie. A.F. reported serving as a cofounder of and owning stock in Alba Therapeutics and serving on scientific advisory boards for NextCure and Viome outside the submitted work. All other authors report no competing interests.Funding StatementThis study was funded by grants from NIH, March of Dimes, Gates Foundation and MassCPR to the authors, as described in the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of MassGeneral Brigham gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.